Cost-utility analysis of Ruconest® (conestat alfa) compared to Berinert® P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema

Postepy Dermatologii i Alergologii

Volumn 30, Issue 3, 2013, Pages 152-158

  Kawalec, Paweł ^a,b   Holko, Przemysław ^a,b   Paszulewicz, Anna ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Centrum HTA w Krakowie   (Poland)

Author keywords

Acute angioedema attacks; Conestat alfa; Cost utility analysis; Hereditary angioedema; Human C1 esterase inhibitor

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR;

ANGIONEUROTIC EDEMA; ARTICLE; COMPARATIVE STUDY; COST UTILITY ANALYSIS; DRUG COST; HEALTH PROGRAM; HUMAN; LIFE EXPECTANCY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SHORT FORM 36; SIMULATION; VISUAL ANALOG SCALE;

EID: 84880091742     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2013.35616     Document Type: Article

References (46)

1. Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy 2005; 94: 498-503. (Pubitemid 40547939)
2. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027-36.
3. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26: 653-68. (Pubitemid 44666309)
4. Official website of Polish Aid Association for Patients with Hereditary Angioedema, http://www.hae.org.pl/ (last access: 1.09.2012).
5. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161: 1153-8.
6. Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patent registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498-503. (Pubitemid 40547939)
7. Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000; 20: 477-85. (Pubitemid 32099713)
8. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100 (Suppl 2): 30-40.
9. Davis AE, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 2010; 104: 886-93.
10. Summary of Product Characteristics - Ruconest? (last updating: 1.09.2012).
11. Obtułowicz K. Hereditary angioedema due to C1 inhibitor deficiency. Diagnostic issues and current treatment. Alergol Immunol 2010; 7: 86-8.
12. Obtułowicz K. Report from international experts' conference for the Hereditary Angioedema. Alergol Immunol 2010; 7: 3-4.
13. Muszyńska A, Fal AM. Hereditary angioedema - treatment. Pol Merkuriusz Lek 2008; 145: 94-6.
14. Szmurło D, Schubert A, Kostrzewska K, et al. Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland. Pol Arch Med Wewn 2011; 121: 345-51.
15. Official website of Main Statistical Office, information about actual 2012 GDP estimation http://www.stat.gov.pl/gus/5840-1338-PLK-HTML.htm (last access: 1.09.2012).
16. Jacobson S, Hall S, Swisher J. Discrete event simulation of health care systems. In: Delay management in healthcare systems. Hall R (ed.). Springer in Health Care Management 2006.
17. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23: 323-32. (Pubitemid 40677051)
18. Le Lay A, Despiegel N, François C, Duru G. Can discrete event imulation be of use in modelling major depression? Cost Eff Resour Alloc 2006; 4: 19.
19. Lesniak W, Bala M, Jaeschke R, et al. Effect of megestrol acetale in patients with cancer anorexia-cachexia syndrome - a systematic review and meta-analysis. Pol Arch Med Wew 2008; 118: 636-44.
20. Gajewski P, Jaeschke R, Brożek J. Basis of EBM, medicine based on scientific data for physicians and medical students. Medycyna Praktyczna 2008.
21. Cochrane Collaboration, Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. March 2011 (http://www.cochrane.org/resources/ handbook/) - last access: 1.09.2012.
22. Guidelines for conducting Health Technology Assessment HTA. Version 2.1. AHTAPol March 2009 (last access: 1.09.2012).
23. Results of C1 1205-01 trial provided by Swedish Orphan Biovitrum Sp. z o.o., Division in Poland (data on file); RhC1INH (Ruconest®) vs. placebo.
24. Results of C1 1304-01 trial provided by Swedish Orphan Biovitrum Sp. z o.o., Division in Poland (data on file); RhC1INH (Ruconest®) vs. placebo.
25. Caballero T, et al. European consensus for gynecologycal and obstetric management of women with hereditary angioedema due to C1-Inhibitor deficiency (HAE): PREHAEAT. J Allergy Clin Immunol 2007; S12.
26. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management. Allergy Asthma Clin Immunol 2010; 6: 24.
27. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38: 540-9. (Pubitemid 28317229)
28. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-4. (Pubitemid 26192522)
29. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8.
30. Bernstein JA, Ritchie B, Levy RJ, et al. Hereditary angioedema: validation of the end point time to onset of relief by correlation with symptom intensity. Allergy Asthma Proc 2011; 32: 36-42.
31. Krassilnikova S, Craig ET, Craig TJ. Summary of the international, prospective Angioedema C1-inhibitor trials 1 and 2 (IMPACT1 and 2). Expert Rev Clin Immunol 2010; 6: 327-34.
32. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91. (Pubitemid 27341818)
33. Dagen C, Craig TJ. Treatment of hereditary angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol 2010; 6: 11.
34. Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009; 49: 1987-95.
35. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-51.
36. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-14.
37. Golicki D, Niewada M, Jakubczyk M, et al. Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study. Pol Arch Med Wewn 2010; 120: 276-81.
38. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the third C1 Esterase Inhibitor Deficiency Workshop and beyond. J Allergy Clin Immunol 2004; 114: 51-131.
39. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci 2003; 29: 235-8. (Pubitemid 37315588)
40. National Health Fund Official Website. Agreement Registry. http://www.nfz.gov.pl/new/index.php?katnr=3&dzialnr=19 (last access: 1.09.2012).
41. thNovember 2011.
42. thFebruary 2012.
43. thMarch 2004 for the goods and services tax.
44. Legal act on drug and medical devices reimbursement - 12.5.2011.
45. Summary of Product Characteristics - Berinert® P (last updating: 1.09.2012).
46. Bowen T, Brosz J, Brosz K, et al. Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol 2010; 6: 20.